{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T17:26:57Z","timestamp":1777829217057,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171301"],"award-info":[{"award-number":["82171301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Improvement and Research","award":["2020-2-1032"],"award-info":[{"award-number":["2020-2-1032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02772-4","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T03:20:43Z","timestamp":1753327243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["uPAR and cFn as candidate protein biomarkers for identifying low response to rtPA in acute ischemic stroke"],"prefix":"10.1186","volume":"30","author":[{"given":"Yilin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziping","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangmin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesario","family":"Borlongan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"1","key":"2772_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","volume":"5","author":"BCV Campbell","year":"2019","unstructured":"Campbell BCV, et al. Ischaemic stroke. Nat Rev Dis Primers. 2019;5(1):70.","journal-title":"Nat Rev Dis Primers"},{"issue":"9958","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","volume":"384","author":"J Emberson","year":"2014","unstructured":"Emberson J, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929\u201335.","journal-title":"Lancet"},{"issue":"9727","key":"2772_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(10)60491-6","volume":"375","author":"KR Lees","year":"2010","unstructured":"Lees KR, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695\u2013703.","journal-title":"Lancet"},{"issue":"3","key":"2772_CR4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1161\/STROKEAHA.120.032810","volume":"52","author":"P Jolugbo","year":"2021","unstructured":"Jolugbo P, Ari\u00ebns RAS. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke. Stroke. 2021;52(3):1131\u201342.","journal-title":"Stroke"},{"issue":"9558","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(07)60120-2","volume":"369","author":"GW Albers","year":"2007","unstructured":"Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet. 2007;369(9558):249\u201350.","journal-title":"Lancet"},{"issue":"17\u201318","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17520363.2024.2389033","volume":"18","author":"Z Tang","year":"2024","unstructured":"Tang Z, et al. Novel metabolic biomarkers for the diagnosis of acute ischemic stroke. Biomark Med. 2024;18(17\u201318):727\u201337.","journal-title":"Biomark Med"},{"issue":"9","key":"2772_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036727","volume":"14","author":"P Garc\u00eda-Rodr\u00edguez","year":"2025","unstructured":"Garc\u00eda-Rodr\u00edguez P, et al. Association of A1AT with poor functional outcome in patients with acute ischemic stroke. J Am Heart Assoc. 2025;14(9): e036727.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2772_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4274\/balkanmedj.galenos.2025.2025-1-36","volume":"42","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, et al. The association between serum pentraxin-3 level at admission and the functional outcome of patients after acute ischemic stroke: a meta-analysis. Balkan Med J. 2025;42(3):201\u201311.","journal-title":"Balkan Med J"},{"issue":"3","key":"2772_CR9","first-page":"495","volume":"15","author":"I Kraljevi\u0107","year":"2025","unstructured":"Kraljevi\u0107 I, et al. Can serum GFAP and UCH-L1 replace CT in assessing acute ischemic stroke severity? Life (Basel). 2025;15(3):495.","journal-title":"Life (Basel)"},{"issue":"3","key":"2772_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/medicina61030514","volume":"61","author":"A Babi\u0107","year":"2025","unstructured":"Babi\u0107 A, et al. Blood biomarkers in ischemic stroke diagnostics and treatment-future perspectives. Medicina (Kaunas). 2025;61(3):514.","journal-title":"Medicina (Kaunas)"},{"issue":"43","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"14219","DOI":"10.1523\/JNEUROSCI.5309-13.2014","volume":"34","author":"F Wu","year":"2014","unstructured":"Wu F, et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci. 2014;34(43):14219\u201332.","journal-title":"J Neurosci"},{"issue":"12","key":"2772_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nrm977","volume":"3","author":"F Blasi","year":"2002","unstructured":"Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932\u201343.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3171\/2016.1.JNS152287","volume":"126","author":"Q Tan","year":"2017","unstructured":"Tan Q, et al. Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage. J Neurosurg. 2017;126(2):548\u201357.","journal-title":"J Neurosurg"},{"issue":"1\u20132","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0165-5728(02)00186-8","volume":"129","author":"JC Garcia-Monco","year":"2002","unstructured":"Garcia-Monco JC, Coleman JL, Benach JL. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 2002;129(1\u20132):216\u201323.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clinbiochem.2009.09.028","volume":"43","author":"FJ Olson","year":"2010","unstructured":"Olson FJ, et al. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem. 2010;43(1\u20132):124\u201330.","journal-title":"Clin Biochem"},{"issue":"12","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1161\/STROKEAHA.112.664094","volume":"43","author":"A Edsfeldt","year":"2012","unstructured":"Edsfeldt A, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke. 2012;43(12):3305\u201312.","journal-title":"Stroke"},{"issue":"2","key":"2772_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH04-09-0592","volume":"93","author":"D Alfano","year":"2005","unstructured":"Alfano D, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost. 2005;93(2):205\u201311.","journal-title":"Thromb Haemost"},{"issue":"1","key":"2772_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2772_CR19","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1177\/0271678X18783653","volume":"39","author":"A Diaz","year":"2019","unstructured":"Diaz A, et al. Urokinase-type plasminogen activator (uPA) protects the tripartite synapse in the ischemic brain via ezrin-mediated formation of peripheral astrocytic processes. J Cereb Blood Flow Metab. 2019;39(11):2157\u201371.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"24","key":"2772_CR20","doi-asserted-by":"publisher","first-page":"9234","DOI":"10.1074\/jbc.RA118.002534","volume":"293","author":"P Merino","year":"2018","unstructured":"Merino P, et al. Urokinase-type plasminogen activator (uPA) promotes ezrin-mediated reorganization of the synaptic cytoskeleton in the ischemic brain. J Biol Chem. 2018;293(24):9234\u201347.","journal-title":"J Biol Chem"},{"issue":"1","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neulet.2007.12.004","volume":"432","author":"N Nagai","year":"2008","unstructured":"Nagai N, et al. Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. Neurosci Lett. 2008;432(1):46\u20139.","journal-title":"Neurosci Lett"},{"issue":"2","key":"2772_CR22","volume":"4","author":"P Merino","year":"2017","unstructured":"Merino P, Diaz A, Yepes M. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain. Receptors Clin Investig. 2017;4(2): e1552.","journal-title":"Receptors Clin Investig"},{"issue":"4","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.thromres.2009.12.017","volume":"125","author":"LM Maurer","year":"2010","unstructured":"Maurer LM, Tomasini-Johansson BR, Mosher DF. Emerging roles of fibronectin in thrombosis. Thromb Res. 2010;125(4):287\u201391.","journal-title":"Thromb Res"},{"issue":"2","key":"2772_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2337\/diacare.24.2.323","volume":"24","author":"SD Kanters","year":"2001","unstructured":"Kanters SD, et al. Plasma levels of cellular fibronectin in diabetes. Diabetes Care. 2001;24(2):323\u20137.","journal-title":"Diabetes Care"},{"issue":"20","key":"2772_CR25","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1182\/blood-2014-10-608653","volume":"125","author":"P Prakash","year":"2015","unstructured":"Prakash P, et al. Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. Blood. 2015;125(20):3164\u201372.","journal-title":"Blood"},{"key":"2772_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.523506","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang L, et al. Association of matrix metalloproteinase 9 and cellular fibronectin and outcome in acute ischemic stroke: a systematic review and meta-analysis. Front Neurol. 2020;11: 523506.","journal-title":"Front Neurol"},{"issue":"7","key":"2772_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/01.STR.0000131656.47979.39","volume":"35","author":"M Castellanos","year":"2004","unstructured":"Castellanos M, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35(7):1671\u20136.","journal-title":"Stroke"},{"issue":"1","key":"2772_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.2388","volume":"216","author":"ES White","year":"2008","unstructured":"White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol. 2008;216(1):1\u201314.","journal-title":"J Pathol"},{"key":"2772_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1938","volume":"342","author":"KS McArthur","year":"2011","unstructured":"McArthur KS, et al. Diagnosis and management of transient ischaemic attack and ischaemic stroke in the acute phase. BMJ. 2011;342: d1938.","journal-title":"BMJ"},{"issue":"1","key":"2772_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jphys.2013.12.012","volume":"60","author":"LK Kwah","year":"2014","unstructured":"Kwah LK, Diong J. National institutes of health stroke scale (NIHSS). J Physiother. 2014;60(1):61.","journal-title":"J Physiother"},{"issue":"7","key":"2772_CR31","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/STROKEAHA.117.017866","volume":"48","author":"JP Broderick","year":"2017","unstructured":"Broderick JP, Adeoye O, Elm J. Evolution of the modified Rankin scale and its use in future stroke trials. Stroke. 2017;48(7):2007\u201312.","journal-title":"Stroke"},{"issue":"4","key":"2772_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00004647-199804000-00004","volume":"18","author":"R Hata","year":"1998","unstructured":"Hata R, et al. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab. 1998;18(4):367\u201375.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"2772_CR33","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1074\/jbc.M116.761650","volume":"292","author":"P Merino","year":"2017","unstructured":"Merino P, et al. Urokinase-type plasminogen activator (uPA) binding to the uPA receptor (uPAR) promotes axonal regeneration in the central nervous system. J Biol Chem. 2017;292(7):2741\u201353.","journal-title":"J Biol Chem"},{"issue":"3","key":"2772_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1242\/dev.116.3.625","volume":"116","author":"Y Sumi","year":"1992","unstructured":"Sumi Y, et al. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development. 1992;116(3):625\u201337.","journal-title":"Development"},{"issue":"6","key":"2772_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1460-9568.1993.tb00529.x","volume":"5","author":"MA Dent","year":"1993","unstructured":"Dent MA, et al. Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain. Eur J Neurosci. 1993;5(6):633\u201347.","journal-title":"Eur J Neurosci"},{"issue":"5","key":"2772_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/dvdy.24114","volume":"243","author":"N Lino","year":"2014","unstructured":"Lino N, et al. uPA-uPAR molecular complex is involved in cell signaling during neuronal migration and neuritogenesis. Dev Dyn. 2014;243(5):676\u201389.","journal-title":"Dev Dyn"},{"issue":"2","key":"2772_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1172\/JCI116637","volume":"92","author":"AP Sappino","year":"1993","unstructured":"Sappino AP, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest. 1993;92(2):679\u201385.","journal-title":"J Clin Invest"},{"issue":"43","key":"2772_CR38","doi-asserted-by":"publisher","first-page":"10310","DOI":"10.1523\/JNEUROSCI.1630-17.2017","volume":"37","author":"A Diaz","year":"2017","unstructured":"Diaz A, et al. A cross talk between neuronal Urokinase-type plasminogen activator (uPA) and astrocytic uPA Receptor (uPAR) promotes astrocytic activation and synaptic recovery in the ischemic brain. J Neurosci. 2017;37(43):10310\u201322.","journal-title":"J Neurosci"},{"issue":"4","key":"2772_CR39","doi-asserted-by":"publisher","first-page":"620","DOI":"10.4103\/1673-5374.266904","volume":"15","author":"M Yepes","year":"2020","unstructured":"Yepes M. Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain. Neural Regen Res. 2020;15(4):620\u20134.","journal-title":"Neural Regen Res"},{"issue":"3","key":"2772_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10571-019-00737-w","volume":"40","author":"RRA Kadir","year":"2020","unstructured":"Kadir RRA, Bayraktutan U. Urokinase plasminogen activator: a potential thrombolytic agent for ischaemic stroke. Cell Mol Neurobiol. 2020;40(3):347\u201355.","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"2772_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1161\/01.STR.0000149615.51204.0b","volume":"36","author":"Y Silva","year":"2005","unstructured":"Silva Y, et al. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke. 2005;36(1):86\u201391.","journal-title":"Stroke"},{"issue":"9","key":"2772_CR42","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1161\/01.STR.0000177870.14967.94","volume":"36","author":"J Serena","year":"2005","unstructured":"Serena J, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005;36(9):1921\u20136.","journal-title":"Stroke"},{"issue":"6","key":"2772_CR43","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/STROKEAHA.106.481556","volume":"38","author":"M Castellanos","year":"2007","unstructured":"Castellanos M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke. 2007;38(6):1855\u20139.","journal-title":"Stroke"},{"key":"2772_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102287","volume":"30","author":"E Fernandes","year":"2020","unstructured":"Fernandes E, et al. Point-of-care quantification of serum cellular fibronectin levels for stratification of ischemic stroke patients. Nanomedicine. 2020;30: 102287.","journal-title":"Nanomedicine"},{"issue":"3","key":"2772_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/85471","volume":"7","author":"T Sakai","year":"2001","unstructured":"Sakai T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med. 2001;7(3):324\u201330.","journal-title":"Nat Med"},{"issue":"1","key":"2772_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.expneurol.2007.05.008","volume":"207","author":"CC Tate","year":"2007","unstructured":"Tate CC, Garc\u00eda AJ, LaPlaca MC. Plasma fibronectin is neuroprotective following traumatic brain injury. Exp Neurol. 2007;207(1):13\u201322.","journal-title":"Exp Neurol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02772-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:08:54Z","timestamp":1757286534000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02772-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Xuanwu Hospital of Capital Medical University granted ethical approval for this study and waived the requirement for written informed consent. The study was performed in line with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"662"}}